BMS-833923

DRUG6 trials

Sponsors

Bristol-Myers Squibb, University Health Network, Toronto

Conditions

Advanced Cancer, Various, NOSBasal Cell Nevus SyndromeEsophageal NeoplasmsLeukemiaSmall Cell Lung CarcinomaStomach Neoplasms

Phase 1

Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

CompletedNCT00884546

Bristol-Myers SquibbAdvanced Cancer, Various, NOS

Start: 2009-07-31End: 2012-03-31Updated: 2016-09-30

A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

CompletedNCT00909402

Bristol-Myers SquibbEsophageal Neoplasms, Stomach Neoplasms

Start: 2009-11-30End: 2012-11-30Updated: 2013-06-21

A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

CompletedNCT00927875

Bristol-Myers SquibbSmall Cell Lung Carcinoma

Start: 2010-02-28End: 2012-09-30Updated: 2013-06-03

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

CompletedNCT01218477

Bristol-Myers SquibbLeukemia

Start: 2011-01-31End: 2013-04-30Updated: 2016-06-17

Phase 2

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

TerminatedNCT01357655

Bristol-Myers SquibbLeukemia

Start: 2011-09-30End: 2016-01-31Updated: 2017-03-14

Unknown Phase

Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome

CompletedNCT02100371

University Health Network, TorontoBasal Cell Nevus Syndrome

Start: 2014-02-28End: 2017-05-31Updated: 2017-07-11